-
公开(公告)号：US11359000B2
公开(公告)日：2022-06-14
申请号：US16366838
申请日：2019-03-27
Applicant: Bristol-Myers Squibb Company
Inventor： Mary Struthers , Jonathan Harry Davis , Michael Louis Doyle , Priyanka Apurva Madia
IPC: C07K14/55 , C07K14/715 , A61K38/20 , A61K38/17 , A61K47/65 , C12N15/62 , A61P37/04 , C07K16/28 , A61K38/00
Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
-
公开(公告)号：US11952420B2
公开(公告)日：2024-04-09
申请号：US17472051
申请日：2021-09-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Achal Pashine , Michael L Gosselin , Aaron P. Yamniuk , Derek A. Holmes , Guodong Chen , Priyanka Apurva Madia , Richard Yu-Cheng Huang , Stephen Michael Carl
CPC classification number: C07K16/2803 , A61K47/6803 , A61P29/00 , C12N15/85 , C07K2317/32 , C07K2317/565 , C07K2317/90 , C07K2317/92
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
-
公开(公告)号：US12202872B2
公开(公告)日：2025-01-21
申请号：US17663384
申请日：2022-05-13
Applicant: Bristol-Myers Squibb Company
Inventor： Mary Struthers , Jonathan Harry Davis , Michael Louis Doyle , Priyanka Apurva Madia
IPC: C07K14/55 , A61K38/17 , A61K38/20 , A61K47/65 , A61P37/04 , C07K14/715 , C07K16/28 , C12N15/62 , A61K38/00
Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
-
Patent Agency Ranking
公开(公告)号：US11155618B2
公开(公告)日：2021-10-26
申请号：US16371964
申请日：2019-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Achal Pashine , Michael L. Gosselin , Aaron P. Yamniuk , Derek A. Holmes , Guodong Chen , Priyanka Apurva Madia , Richard Yu-Cheng Huang , Stephen Michael Carl
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
-
公开(公告)号：US11919954B2
公开(公告)日：2024-03-05
申请号：US17472302
申请日：2021-09-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Achal Pashine , Michael L. Gosselin , Aaron P. Yamniuk , Derek A. Holmes , Guodong Chen , Priyanka Apurva Madia , Richard Yu-Cheng Huang , Stephen Michael Carl
CPC classification number: C07K16/2803 , A61K47/6803 , A61P29/00 , C12N15/85 , C07K2317/32 , C07K2317/565 , C07K2317/90 , C07K2317/92
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
-
公开(公告)号：US10787494B2
公开(公告)日：2020-09-29
申请号：US16435420
申请日：2019-06-07
Applicant: Bristol-Myers Squibb Company
Inventor： Mary Struthers , Jonathan Harry Davis , Michael Louis Doyle , Priyanka Apurva Madia
IPC: A61K38/20 , A61K38/17 , C07K14/55 , C07K14/715 , C12N15/62 , A61K47/65 , A61P37/04 , C07K16/28 , A61K38/00
Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
-
公开(公告)号：US20190359672A1
公开(公告)日：2019-11-28
申请号：US16435420
申请日：2019-06-07
Applicant: Bristol-Myers Squibb Company
Inventor： Mary STRUTHERS , Jonathan Harry Davis , Michael Louis Doyle , Priyanka Apurva Madia
IPC: C07K14/55 , C07K16/28 , A61P37/04 , A61K47/65 , C07K14/715
Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
-
公开(公告)号：US20190300608A1
公开(公告)日：2019-10-03
申请号：US16371964
申请日：2019-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Achal Pashine , Michael L. Gosselin , Aaron P. Yamniuk , Derek A. Holmes , Guodong Chen , Priyanka Apurva Madia
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.021 seconds)
